InCarda Therapeutics Email Format

Biotechnology ResearchUtah, United States11-50 Employees

InCarda Therapeutics is a clinical-stage biotechnology company focused on delivering inhaled therapies for cardiovascular disease, with an emphasis on rapid and safe pharmacological cardioversion of atrial fibrillation. The company is based in West Valley City, Utah, and pursues non-invasive approaches intended to quickly restore normal heart rhythm in AF patients. By pursuing novel drug-delivery methods, InCarda aims to provide timely rhythm control while reducing the need for invasive procedures.

Atrial fibrillation affects more than ten million people in the United States, underscoring the potential demand for improved treatment options in this area. Operating in the biotechnology research sector, InCarda develops therapies for cardiovascular indications and has engaged in collaborations to support its programmatic development, such as a 2022 partnership involving remote patient monitoring. In December 2024 the company named Dr. Myles Greenberg as chief executive officer, marking a leadership change at the clinical-stage company.

Get verified InCarda Therapeutics emails free

Company overview Employee directory